We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

206 hedge funds and large institutions have $2.36B invested in IDEAYA Biosciences in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 94 increasing their positions, 56 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 56

42% more call options, than puts

Call options by funds: $1.07M | Put options by funds: $753K

3% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 35

1% less funds holding

Funds holding: 209206 (-3)

2.37% less ownership

Funds ownership: 108.77%106.39% (-2.4%)

19% less capital invested

Capital invested by funds: $2.91B → $2.36B (-$548M)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
206
Holders Change
-3
Holders Change %
-1.44%
% of All Funds
2.71%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
34
Increased
94
Reduced
56
Closed
35
Calls
$1.07M
Puts
$753K
Net Calls
+$315K
Net Calls Change
-$711K
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$7.06M +$5.52M +194,913 +244%
N
52
Nuveen
North Carolina
$6.92M +$78.7K +2,779 +1%
Axa
53
Axa
France
$6.42M +$1.18M +41,722 +20%
WCM Investment Management
54
WCM Investment Management
California
$6.03M +$6.85M +241,894 New
SCM
55
Superstring Capital Management
New York
$5.84M +$6.43M +227,102 New
Bank of New York Mellon
56
Bank of New York Mellon
New York
$5.82M -$1.41M -49,932 -18%
Schroder Investment Management Group
57
Schroder Investment Management Group
United Kingdom
$5.72M -$412K -14,537 -6%
RI
58
RTW Investments
New York
$5.14M
Barclays
59
Barclays
United Kingdom
$5.11M +$498K +17,586 +10%
D.E. Shaw & Co
60
D.E. Shaw & Co
New York
$4.64M -$11M -387,055 -68%
Squarepoint
61
Squarepoint
New York
$4.6M +$937K +33,088 +23%
Neuberger Berman Group
62
Neuberger Berman Group
New York
$4.25M +$1.26M +44,588 +37%
PIM
63
Platinum Investment Management
Australia
$3.92M +$226K +7,996 +6%
Wells Fargo
64
Wells Fargo
California
$3.87M -$87.6K -3,093 -2%
Swiss National Bank
65
Swiss National Bank
Switzerland
$3.84M +$467K +16,500 +12%
NICM
66
Neo Ivy Capital Management
New York
$3.36M +$3.7M +130,806 New
Citigroup
67
Citigroup
New York
$3.24M +$1.57M +55,482 +78%
Millennium Management
68
Millennium Management
New York
$3.16M -$6.2M -219,069 -64%
SCM
69
Sio Capital Management
New York
$3.16M
GAI
70
General American Investors
New York
$3.09M +$857K +30,261 +34%
Rafferty Asset Management
71
Rafferty Asset Management
New York
$3.04M -$221K -7,792 -6%
JF
72
Jump Financial
Illinois
$2.95M +$1.27M +45,035 +64%
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
$2.92M +$16.6K +585 +0.5%
TI
74
Trexquant Investment
Connecticut
$2.75M +$3.03M +107,147 New
Prudential Financial
75
Prudential Financial
New Jersey
$2.62M +$510K +18,000 +21%

IDYA Hedge Fund Activity: Q4 2024 in Review

206 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q4 2024, worth a combined $2.36B — down 19% from $2.91B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of IDYA and 34 opened new positions — a net loss of 1 holder — while 56 trimmed existing stakes and 94 added.

The largest buyer was Morgan Stanley, adding an estimated $33.8M. The largest seller was BVF Inc, exiting entirely with an estimated $44.7M sold.

  • 206 institutional investors held IDEAYA Biosciences (IDYA) as of Q4 2024, down from 209 in Q3 2024.
  • Funds reported $2.36B of IDEAYA Biosciences stock for Q4 2024, down 19% quarter-over-quarter.
  • 34 funds opened new IDEAYA Biosciences positions in Q4 2024 and 35 closed out, a net change of -1 holder.
  • The largest IDEAYA Biosciences buyer in Q4 2024 was Morgan Stanley, an estimated $33.8M added.
  • The largest IDEAYA Biosciences seller in Q4 2024 was BVF Inc, an estimated $44.7M sold.

Based on aggregated 13F filings for Q4 2024.